E
Eduardo Davila
Researcher at University of Maryland, Baltimore
Publications - 47
Citations - 1650
Eduardo Davila is an academic researcher from University of Maryland, Baltimore. The author has contributed to research in topics: T cell & Cytotoxic T cell. The author has an hindex of 18, co-authored 38 publications receiving 1320 citations. Previous affiliations of Eduardo Davila include University of Colorado Denver & Veterans Health Administration.
Papers
More filters
Journal ArticleDOI
TLR agonists: our best frenemy in cancer immunotherapy
TL;DR: Several criteria must be considered when selecting TLR agonists for developing effective immunotherapeutic strategies against cancer, based on evidence from preclinical models and clinical trials.
Journal ArticleDOI
Redirecting gene-modified T cells toward various cancer types using tagged antibodies.
Koji Tamada,Degui Geng,Yukimi Sakoda,Navneeta Bansal,Ratika Srivastava,Zhaoyang Li,Eduardo Davila +6 more
TL;DR: These studies highlight an applicability of anti-tag CAR technology to treat patients with different types of cancers and a possibility to regulate CAR T-cell functions with competing FITC molecules.
Journal ArticleDOI
IL-1 Receptor-Associated Kinase Signaling and Its Role in Inflammation, Cancer Progression, and Therapy Resistance
TL;DR: It is proposed that dysregulated activation of the IRAK signaling pathway in cancer cells contributes to disease progression by creating a highly inflammatory tumor environment.
Patent
Universal anti-tag chimeric antigen receptor-expressing t cells and methods of treating cancer
Eduardo Davila,Koji Tamada +1 more
TL;DR: In this paper, a universal, yet adaptable, anti-tag chimeric antigen receptor (AT-CAR) system which provides T cells with the ability and specificity to recognize and kill target cells, such as tumor cells, that have been marked by tagged antibodies.
Journal ArticleDOI
Cod glycopeptide with picomolar affinity to galectin-3 suppresses T-cell apoptosis and prostate cancer metastasis
Prasun Guha,Engin Kaptan,Gargi Bandyopadhyaya,Sabina Kaczanowska,Eduardo Davila,Keyata Thompson,Stuart S. Martin,Dhananjaya V. Kalvakolanu,Dhananjaya V. Kalvakolanu,Gerardo R. Vasta,Hafiz Ahmed +10 more
TL;DR: To block gal3-mediated interactions, a glycopeptide from cod is purified that binds gal3 with picomolar affinity and should be a promising antimetastatic agent for the treatment of various cancers, including prostate adenocarcinoma.